Eli Lilly Solidifies Leadership in Obesity Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Data Released: Eli Lilly presented detailed clinical trial data for its experimental drug retatrutide at the American Diabetes Association meeting, confirming that its once-weekly injection offers superior weight loss prospects compared to existing medications, further solidifying its leadership in the obesity drug market.
- Increasing Market Competition: While Lilly maintains a leading position, new data from Roche, AstraZeneca, and Pfizer indicates intensifying competition in the obesity drug market, which may lead to price reductions and more options, potentially impacting Lilly's market share.
- Diverse Patient Choices: Roche's enicepatide demonstrated a 22.7% weight loss in mid-stage trials, while both Lilly and Novo Nordisk are committed to providing multiple drug options to cater to diverse patient needs, emphasizing the importance of personalized treatment.
- Challenges in Side Effect Management: Despite breakthroughs in weight loss efficacy, many drugs still face significant side effect issues, particularly gastrointestinal discomfort associated with GLP-1 and GIP hormones, leading to discontinuation rates as high as 40%, posing challenges for market acceptance of these therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1149.150
Low
950.00
Averages
1192
High
1500
Current: 1149.150
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves New Dosing Regimen for EBGLYSS
- New Dosing Regimen: EBGLYSS (lebrikizumab-lbkz) has received FDA approval for a new regimen allowing a single 250 mg injection every eight weeks, reducing the treatment frequency to as few as six maintenance injections per year, significantly enhancing patient quality of life.
- Clinical Data Support: This approval is based on clinical data from the 32-week ADjoin long-term trial, demonstrating that the new dosing regimen maintains safety and efficacy comparable to the every-four-week schedule, ensuring sustained disease control for patients.
- Market Potential: As a first-line biologic treatment for moderate-to-severe atopic dermatitis, EBGLYSS is expected to attract more patients, further solidifying Lilly's market position in dermatological therapies.
- Patient Support Program: Lilly offers co-pay assistance through its EBGLYSS patient support services, ensuring that 94% of commercially insured patients have coverage, reflecting the company's commitment to health equity and affordability for patients.
See More
FDA Approves Ebglyss for Bi-Monthly Eczema Treatment
- Therapeutic Innovation: The FDA has approved Eli Lilly's Ebglyss for bi-monthly maintenance dosing, allowing patients to manage eczema with only six injections per year, significantly reducing treatment frequency and enhancing patient adherence and quality of life.
- Clinical Support: This approval is backed by data from the ADjoin late-stage trial extension, which evaluated Ebglyss administered every eight weeks versus every four weeks, demonstrating efficacy in patients with moderate-to-severe atopic dermatitis.
- Market Potential: The approval opens new market opportunities for Eli Lilly in dermatological treatments, particularly bolstered by its partnership with Spanish pharma company Almirall, enhancing its competitive position in the European market.
- Patient Benefit: Adrienne Brown, president of Lilly Immunology, noted that this therapy allows patients with moderate-to-severe atopic dermatitis to avoid starting with prescription topicals, greatly simplifying treatment regimens and addressing the demand for convenient therapies.
See More
Eli Lilly Solidifies Leadership in Obesity Drug Market
- Clinical Trial Data Released: Eli Lilly presented detailed clinical trial data for its experimental drug retatrutide at the American Diabetes Association meeting, confirming that its once-weekly injection offers superior weight loss prospects compared to existing medications, further solidifying its leadership in the obesity drug market.
- Increasing Market Competition: While Lilly maintains a leading position, new data from Roche, AstraZeneca, and Pfizer indicates intensifying competition in the obesity drug market, which may lead to price reductions and more options, potentially impacting Lilly's market share.
- Diverse Patient Choices: Roche's enicepatide demonstrated a 22.7% weight loss in mid-stage trials, while both Lilly and Novo Nordisk are committed to providing multiple drug options to cater to diverse patient needs, emphasizing the importance of personalized treatment.
- Challenges in Side Effect Management: Despite breakthroughs in weight loss efficacy, many drugs still face significant side effect issues, particularly gastrointestinal discomfort associated with GLP-1 and GIP hormones, leading to discontinuation rates as high as 40%, posing challenges for market acceptance of these therapies.
See More
Novo Nordisk Takes Legal Action in South Africa
- Legal Action Context: Novo Nordisk has filed a lawsuit in the South African High Court to prevent local pharmacy iDexis from manufacturing and selling unapproved weight-loss products containing semaglutide, highlighting serious concerns regarding patient safety and product quality.
- Regulatory Compliance Issues: South Africa imposes strict restrictions on the compounding of drug ingredients, and iDexis is accused of violating laws by engaging in large-scale manufacturing and distribution of unregistered medicines, posing a potential threat to public health.
- Market Response: Following a surge in demand for drugs like Eli Lilly's Mounjaro and Novo's Wegovy, the price of Wegovy's lowest injected dose has dropped from 3,090 rand to 1,873 rand, prompting some patients to switch to cheaper compounded versions, thus creating a gray market.
- Regulatory Authority Actions: A joint inspection by the South African Health Products Regulatory Authority and the Pharmacy Council found serious deficiencies in iDexis's quality and safety practices, leading to product seizures and recalls, demonstrating a strong stance against illegal drug manufacturing.
See More
Eli Lilly Receives FDA Approval for New Dosing Schedule
- New Dosing Schedule Approval: Eli Lilly announced that the FDA has approved an every-eight-week maintenance dosing schedule for EBGLYSS (lebrikizumab-lbkz) for patients aged 12 and older weighing at least 40 kg, significantly reducing the frequency of administration and enhancing treatment convenience for patients.
- Significant Sales Growth: EBGLYSS sales surged 141% year-over-year to $145 million in Q1, reflecting strong market demand for the drug, which also supported the company's overall revenue growth of 56% to $19.80 billion.
- Clinical Data Support: The approval was backed by longitudinal data from the extended ADjoin Phase 3 trial, demonstrating the safety and efficacy of the every-eight-week dosing regimen, with no new safety signals observed during the 32-week observation period, further bolstering market confidence in the drug.
- Market Exclusivity: Eli Lilly holds exclusive rights for the development and commercialization of EBGLYSS in the U.S., while Almirall has licensed rights for dermatological indications in Europe, a strategic move that will help the company expand its market share and enhance brand influence globally.
See More
FDA Approves New Dosing Option for Ebglyss
- Dosing Update: The FDA has approved a new maintenance dosing option for Ebglyss, allowing patients aged 12 and older with moderate-to-severe atopic dermatitis to receive injections every eight weeks, significantly reducing treatment frequency to as few as six injections per year, enhancing patient convenience and adherence.
- Clinical Data Support: This approval is backed by data from the Phase 3 ADjoin extension study, which evaluated both four-week and eight-week dosing over a 32-week period, showing consistent safety findings with no new safety signals or treatment discontinuations, ensuring patient safety.
- Patient Management Flexibility: Medical experts involved in the study noted that the extended dosing option offers a more flexible approach for managing chronic symptoms, while patient advocates highlighted the reduced treatment burden and improved quality of life due to fewer injections.
- Market Reaction: Despite LLY's stock price declining by 0.39% during regular trading, retail sentiment remains bullish, with a 1.7% increase in watcher count and a 580% surge in message volume over the past month, indicating positive market reception to the new dosing option for Ebglyss.
See More
FDA Approves New Dosing Regimen for EBGLYSS
- New Dosing Regimen: EBGLYSS (lebrikizumab-lbkz) has received FDA approval for a new regimen allowing a single 250 mg injection every eight weeks, reducing the treatment frequency to as few as six maintenance injections per year, significantly enhancing patient quality of life.
- Clinical Data Support: This approval is based on clinical data from the 32-week ADjoin long-term trial, demonstrating that the new dosing regimen maintains safety and efficacy comparable to the every-four-week schedule, ensuring sustained disease control for patients.
- Market Potential: As a first-line biologic treatment for moderate-to-severe atopic dermatitis, EBGLYSS is expected to attract more patients, further solidifying Lilly's market position in dermatological therapies.
- Patient Support Program: Lilly offers co-pay assistance through its EBGLYSS patient support services, ensuring that 94% of commercially insured patients have coverage, reflecting the company's commitment to health equity and affordability for patients.
See More
FDA Approves Ebglyss for Bi-Monthly Eczema Treatment
- Therapeutic Innovation: The FDA has approved Eli Lilly's Ebglyss for bi-monthly maintenance dosing, allowing patients to manage eczema with only six injections per year, significantly reducing treatment frequency and enhancing patient adherence and quality of life.
- Clinical Support: This approval is backed by data from the ADjoin late-stage trial extension, which evaluated Ebglyss administered every eight weeks versus every four weeks, demonstrating efficacy in patients with moderate-to-severe atopic dermatitis.
- Market Potential: The approval opens new market opportunities for Eli Lilly in dermatological treatments, particularly bolstered by its partnership with Spanish pharma company Almirall, enhancing its competitive position in the European market.
- Patient Benefit: Adrienne Brown, president of Lilly Immunology, noted that this therapy allows patients with moderate-to-severe atopic dermatitis to avoid starting with prescription topicals, greatly simplifying treatment regimens and addressing the demand for convenient therapies.
See More
Eli Lilly Solidifies Leadership in Obesity Drug Market
- Clinical Trial Data Released: Eli Lilly presented detailed clinical trial data for its experimental drug retatrutide at the American Diabetes Association meeting, confirming that its once-weekly injection offers superior weight loss prospects compared to existing medications, further solidifying its leadership in the obesity drug market.
- Increasing Market Competition: While Lilly maintains a leading position, new data from Roche, AstraZeneca, and Pfizer indicates intensifying competition in the obesity drug market, which may lead to price reductions and more options, potentially impacting Lilly's market share.
- Diverse Patient Choices: Roche's enicepatide demonstrated a 22.7% weight loss in mid-stage trials, while both Lilly and Novo Nordisk are committed to providing multiple drug options to cater to diverse patient needs, emphasizing the importance of personalized treatment.
- Challenges in Side Effect Management: Despite breakthroughs in weight loss efficacy, many drugs still face significant side effect issues, particularly gastrointestinal discomfort associated with GLP-1 and GIP hormones, leading to discontinuation rates as high as 40%, posing challenges for market acceptance of these therapies.
See More
Novo Nordisk Takes Legal Action in South Africa
- Legal Action Context: Novo Nordisk has filed a lawsuit in the South African High Court to prevent local pharmacy iDexis from manufacturing and selling unapproved weight-loss products containing semaglutide, highlighting serious concerns regarding patient safety and product quality.
- Regulatory Compliance Issues: South Africa imposes strict restrictions on the compounding of drug ingredients, and iDexis is accused of violating laws by engaging in large-scale manufacturing and distribution of unregistered medicines, posing a potential threat to public health.
- Market Response: Following a surge in demand for drugs like Eli Lilly's Mounjaro and Novo's Wegovy, the price of Wegovy's lowest injected dose has dropped from 3,090 rand to 1,873 rand, prompting some patients to switch to cheaper compounded versions, thus creating a gray market.
- Regulatory Authority Actions: A joint inspection by the South African Health Products Regulatory Authority and the Pharmacy Council found serious deficiencies in iDexis's quality and safety practices, leading to product seizures and recalls, demonstrating a strong stance against illegal drug manufacturing.
See More
Eli Lilly Receives FDA Approval for New Dosing Schedule
- New Dosing Schedule Approval: Eli Lilly announced that the FDA has approved an every-eight-week maintenance dosing schedule for EBGLYSS (lebrikizumab-lbkz) for patients aged 12 and older weighing at least 40 kg, significantly reducing the frequency of administration and enhancing treatment convenience for patients.
- Significant Sales Growth: EBGLYSS sales surged 141% year-over-year to $145 million in Q1, reflecting strong market demand for the drug, which also supported the company's overall revenue growth of 56% to $19.80 billion.
- Clinical Data Support: The approval was backed by longitudinal data from the extended ADjoin Phase 3 trial, demonstrating the safety and efficacy of the every-eight-week dosing regimen, with no new safety signals observed during the 32-week observation period, further bolstering market confidence in the drug.
- Market Exclusivity: Eli Lilly holds exclusive rights for the development and commercialization of EBGLYSS in the U.S., while Almirall has licensed rights for dermatological indications in Europe, a strategic move that will help the company expand its market share and enhance brand influence globally.
See More
FDA Approves New Dosing Option for Ebglyss
- Dosing Update: The FDA has approved a new maintenance dosing option for Ebglyss, allowing patients aged 12 and older with moderate-to-severe atopic dermatitis to receive injections every eight weeks, significantly reducing treatment frequency to as few as six injections per year, enhancing patient convenience and adherence.
- Clinical Data Support: This approval is backed by data from the Phase 3 ADjoin extension study, which evaluated both four-week and eight-week dosing over a 32-week period, showing consistent safety findings with no new safety signals or treatment discontinuations, ensuring patient safety.
- Patient Management Flexibility: Medical experts involved in the study noted that the extended dosing option offers a more flexible approach for managing chronic symptoms, while patient advocates highlighted the reduced treatment burden and improved quality of life due to fewer injections.
- Market Reaction: Despite LLY's stock price declining by 0.39% during regular trading, retail sentiment remains bullish, with a 1.7% increase in watcher count and a 580% surge in message volume over the past month, indicating positive market reception to the new dosing option for Ebglyss.
See More
